Peptide CDMO Market Size, Share, Growth, And Industry Analysis By Type (LPPS, SPPS, and Mixed Phase) By Application (Pharmaceutical Industry, Cosmetics Industry, and Others), Regional Insights and Forecast From 2025 To 2033

• 

   Request a Free Sample To Get More Information on this Market

PEPTIDE CDMO MARKET REPORT OVERVIEW

The global peptide cdmo market size is predicted to reach USD 20.14 billion by 2033 from USD 3.81 billion in 2024, registering a CAGR of 20.3% during the forecast period from 2025 to 2033.

The rising demand for peptide-based therapies has led to tremendous expansion in the Peptide CDMO market in recent years. Contract Development and Manufacturing Organizations (CDMOs) are essential in the peptide business since they offer knowledge and services for creating peptide pharmaceuticals. Generally, there are two types of peptide CDMOs: integrated CDMOs and freestanding CDMOs. Integrated CDMOs provide full-service solutions that cover the entire peptide drug development process, from discovery to commercialization.

These businesses have internal resources for formulation development, regulatory support, and peptide synthesis. Separate CDMOs focus on particular facets of peptide manufacture, like peptide synthesis or formulation development. They work with other CDMOs or pharmaceutical businesses to offer an extensive selection of services. The individual requirements of the drug development program will determine whether integrated or standalone CDMOs are the best option. When there is a need for seamless collaboration between various stages of drug development, integrated CDMOs are preferred. Standalone CDMOs can be easily included in the overall drug development process and are appropriate for initiatives that call for knowledge in a particular field.

COVID-19 IMPACT

"Disrupted Supply Chains And Manufacturing Operations And The Lockdown Measures Hampered The Market Growth"

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the Peptide CDMO market growth and demand returning to pre-pandemic levels once the pandemic is over.

The COVID-19 pandemic has significantly impacted this market. While the need for peptide-based therapies has grown, the pandemic has affected production processes and supply chains. The development and supply of peptide medications have been delayed due to the lockdown measures implemented by several nations. Additionally, resources and attention have been diverted from other therapeutic areas, such as peptides, due to the focus on COVID-19 therapies and vaccines. However, given the rising need for peptide-based treatments, this market's long-term prospects are still promising.

LATEST TRENDS

"Increasing Adoption Of Automation And Digitalization In Peptide Manufacturing Fuels Boosts Market Expansion"

The growing adoption of automation and digitalization in peptide manufacturing is one of the newest trends in the Peptide CDMO industry. Automation technologies, such as high-throughput peptide synthesizers and robotic systems, make it possible to produce peptides more quickly and effectively. Additionally, these technologies guarantee constant quality while lowering the possibility of human error. On the other side, digitization makes data-driven decision-making easier and enhances process control. CDMOs are better able to increase production, reduce costs, and hasten the development of peptide pharmaceuticals by incorporating automation and digitalization. The increased emphasis on individualized treatment is another new trend in the peptide CDMO industry. Due to their ability to be specifically designed to target particular disease pathways or patient populations, peptides offer special advantages in personalized therapeutics.

PEPTIDE CDMO MARKET SEGMENTATION

By Type

The Peptide CDMO market can be segmented into LPPS, SPPS, and mixed phase. Among these, the LPPS is projected to experience rapid growth through 2033.

By Application

The market can be divided based on application into pharmaceutical industry, cosmetics industry, and others. The pharmaceutical industry is expected to hold the most Peptide CDMO market share in the upcoming years.

DRIVING FACTORS

"Increasing Prevalence Of Chronic Diseases And The Need For More Effective Treatment Options Propels Market Expansion"

More effective treatment options and the rising frequency of chronic diseases are needed. The capacity to target intracellular pathways, great specificity, and minimal toxicity of peptide-based therapies are only a few benefits. As a result, peptide medications are increasingly in demand across a range of therapeutic fields, including oncology, cardiovascular disease, and metabolic disorders. Through the provision of knowledge in the development and production of peptide drugs, CDMOs play a crucial part in satisfying this demand.

"Rising Investment In Biopharmaceutical Research And Development Fuels Market Growth"

A growing amount of money is being invested in biopharmaceutical research and development. Biologics, particularly peptides, are receiving more attention from the pharmaceutical sector because they have distinctive therapeutic possibilities. More specialized manufacturing skills are now required due to increased investment in developing peptide-based medicines. CDMOs are well-positioned to assist biopharmaceutical businesses in developing and producing peptide therapeutics because of their knowledge and infrastructure. This market is anticipated to increase in the upcoming years due to the partnership between CDMOs and pharmaceutical firms.

RESTRAINING FACTOR

"Complexity And Cost Of Peptide Manufacturing And Regulatory Challenges Hinder Market Growth"

Although this market is expected to increase, several considerations must be considered. The difficulty and expense of peptide production is one of the key obstacles. Inherently more difficult to produce than tiny molecules, peptides call for particular tools and knowledge. Effective and scalable production procedures are essential to address the rising demand for peptide pharmaceuticals. Furthermore, the price of producing peptides might be significant, which restricts the availability of peptide-based medicines in particular areas. Regulatory issues also constrain this market. Peptide medications must adhere to strict regulatory standards, which include quality assurance, analytical testing, and documentation.

• 

   Request a Free Sample To Get Analysis on Major Geographic Market

PEPTIDE CDMO MARKET REGIONAL INSIGHTS

"North America To Dominate Market Due To The Increasing Prevalence Of Chronic Diseases And The Need For More Effective Treatment Options"

The U.S. holds the Peptide CDMO market share, and factors driving the market growth in this region include the increasing prevalence of chronic diseases and the need for more effective treatment options. The rising incidence of chronic illnesses and the requirement for more efficient treatment alternatives. The benefits of peptide-based therapies are high specificity, low toxicity, and the capacity to target intracellular circuits. Due to this, there is an increasing need for peptide medications in many therapeutic fields, including oncology, cardiovascular illness, and metabolic disorders. CDMOs play a crucial part in satisfying this demand by offering knowledge in peptide drug research and production.

KEY INDUSTRY PLAYERS

"Key Players Focus on Partnerships to Gain a Competitive Advantage "

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

List of Top Peptide CDMO Companies

• Chengdu Shengnuo Biotechnology Co., Ltd (China)
• Jiangsu Nuotai Ao Nuo Biopharmaceutical Co., Ltd (China)
• PolyPeptide (Sweden)
• Thermo Fisher Pharma (U.S.)
• Biopeptek (U.S.)
• Alabiochem (China)
• ScinoPharm (Taiwan)
• CordenPharma (Switzerland)
• Piramal Pharma (India)
• Space Peptides (Australia)
• Bachem (Switzerland)
• Provepharm (France)
• CPC SCIENTIFIC (U.S.)
• CBL (China)
• Alpha Biophama (U.S.)
• AmbioPharm (U.S.)
• Aurigene Pharmaceutical Services (India)

REPORT COVERAGE

This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting factors like segmentation, opportunities, industrial developments, trends, growth, size, share, and restraints. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.